ONCOLYTICS BIOTECH INC 8-K

What Happened

• On June 1, 2026, Oncolytics Biotech Inc. filed a Form 8-K and issued a press release announcing initial preclinical data showing activity for its oncolytic virus candidate pelareorep in combination with RAS inhibitor modalities. The company said it plans additional studies to evaluate pelareorep in combination with multiple RAS‑targeted agents.

Key Details

• Form 8-K filed and press release issued on June 1, 2026 (Exhibit 99.1 attached).
• Announcement covers initial preclinical (non‑clinical) data for pelareorep when combined with RAS inhibitor approaches.
• Company plans further preclinical studies to evaluate combinations of pelareorep with multiple RAS‑targeted agents.
• The filing was signed by CFO Kirk Look.

Why It Matters

• This is an R&D milestone: the company is reporting early (preclinical) combination data and signaling a program of follow‑on studies, which can create future clinical development catalysts.
• The update does not include clinical results, timelines, or financial impacts, so it is an early technical development rather than a near‑term commercial or revenue event.
• Investors should view this as progress on Oncolytics’ pipeline strategy (combination approaches with RAS‑targeted agents) and watch for upcoming study details or clinical plans that could drive further news.